In the spirit of the progenitor of Budda, Mohammed, and Christ, accept that the purse is a tool of suffering.
This new book by Jim Mellon and Al Chalabi is a layman’s guide to longevity. It investigates the new technologies and explains how to benefit from the life extending technologies both personally and professionally. It helps readers unravel the science, offers ideas on potential investment and reveals the views of the key opinion leaders.
The state of the immune system is an important determinant of aging. With age, immune function both declines in effectiveness and becomes inflammatory. Chronic inflammation accelerates the progression of all of the common age-related diseases. It disrupts tissue maintenance and regeneration, to pick one of many examples. It is likely that a sizable component of variation in aging arises from the differences between individuals in the degree to which the immune system has become damaged and dysfunctional.
Some of this immune aging is a matter of the burden of exposure to more rather than fewer pathogens over a lifetime: persistent infections in particular, such as cytomegalovirus and other herpesviruses, appear to drive immune aging. Some immune aging stems from the atrophy of the thymus, the organ responsible for maturation of T cells. A lesser volume of active thymic tissue means fewer new T cells to take up an effective defense of the body. Some immune aging is due to failure of barriers in the gut, allowing gut bacteria to trigger inflammatory activity. Some immune aging arises from cellular senescence among immune cells, turning them into harmful centers of inflammatory signaling. All of these issues have potential solutions, but, as in all matters related to aging, far too little funding and attention are given to the relevant development programs.
These days, it seems anyone wanting to launch rockets will inevitably be compared to Elon Musk and Jeff Bezos, especially if rocket launching isn’t the only business interest on the agenda. Musk has Tesla plus SpaceX, and Bezos has Amazon plus Blue Origin. Now, meet Mark Russell, a disciple of Bezos and rocket engineer who founded HyperSciences, a drilling company that uses aerospace technology to both quickly extract underground geothermal energy and put payloads into orbit at low cost.
The idea of leveraging Earth’s geothermal energy is not a new concept, but the expense and time required to reach the depth needed have been prohibitively expensive. That’s where HyperSciences comes in.
Russell and his team have developed a low-cost, multi-purpose projectile called the HyperDrone that can accelerate to velocities over five times the speed of sound and pulverize hard rock via their HyperDrill. This will enable tunneling speeds that are 5–10 times quicker than conventional methods, and more importantly, it opens up significant market viability in other industries that could benefit, namely when that acceleration is pointed skyward. NASA has already recognized this potential and is a current investor and major partner of HyperSciences.
Artificial intelligence (AI) aims to mimic human cognitive functions. It is bringing a paradigm shift to healthcare, powered by increasing availability of healthcare data and rapid progress of analytics techniques. We survey the current status of AI applications in healthcare and discuss its future. AI can be applied to various types of healthcare data (structured and unstructured). Popular AI techniques include machine learning methods for structured data, such as the classical support vector machine and neural network, and the modern deep learning, as well as natural language processing for unstructured data. Major disease areas that use AI tools include cancer, neurology and cardiology. We then review in more details the AI applications in stroke, in the three major areas of early detection and diagnosis, treatment, as well as outcome prediction and prognosis evaluation. We conclude with discussion about pioneer AI systems, such as IBM Watson, and hurdles for real-life deployment of AI.
The crowd didn’t much care either way. During the Q&A, an audience member asked Hotz if he would consider partnering with transhumanists — people who believe in humanity’s eventual evolution by way of merging the body and mind with robotics and AI — to found his church. Hotz was rather ambivalent to the idea; perhaps he didn’t think people would take him at his word. But if he does a start a church, the sermon he gave at SXSW yesterday was delivered to a room of would-be believers.
“Jailbreak the simulation”
The only patients to have taken the new drug so far are lab mice. But even when the mice had been exposed to lethal levels of the flu, 100 percent of the ones treated with the new treatment survived.
Promisingly, according to NPR, the new treatment was also effective at treating human lung cells grown in the lab — potentially paving the way to human trials.
“It’s a really interesting study,” Jesse Bloom, a virologist at the Fred Hutchinson Cancer Research Center who wasn’t involved with the research, told NPR. “We need more drugs in the fight against flu, and this approach could provide them.”
What’s most worrisome, one source told MIT Tech, was that the malware crosses a new ethical line.
“Targeting safety systems just seemed to be off limits morally and really hard to do technically,” Joe Slowik, a former information warfare officer in the US Navy who now works at Dragos, an industrial cybersecurity firm that’s been tracking the spread of Triton, told the magazine.
Dr. Alan Green’s patients travel from around the country to his tiny practice in Queens, N.Y., lured by the prospect of longer lives.
Over the past two years, more than 200 patients have flocked to see Green after learning that two drugs he prescribes could possibly stave off aging. One 95-year-old was so intent on keeping her appointment that she asked her son to drive her from Maryland after a snowstorm had closed the schools.
Green is among a small but growing number of doctors who prescribe drugs “off-label” for their possible anti-aging effects. Metformin is typically prescribed for diabetes, and rapamycin prevents organ rejection after a transplant, but doctors can prescribe drugs off-label for other purposes—in this case, for “aging.”
